Skip to Content
Biotechnology and health

23andMe Expands its Data Mining Operations

The personal genetics company purchased disease-community website CureTogether earlier this week.

Personal genetics company 23andMe bought a patient social networking site called CureTogether earlier this week, a move that will expand the Silicon Valley-based company’s ability to mine data from its patients for its own research.

CureTogether is an online forum with some 25,000 members who share information about their illness, and personal anecdotes about the effects of treatments and lifestyle choices on their symptoms.

23andMe sells DNA tests directly to consumers who send a spit sample to the company for genomic screening of up to 1 million genetic variants, which are a mix of both recreational (e.g. the genetic basis for tongue rolling) and serious medical traits (e.g. genetic factors associated with Parkinson’s Disease) as well as variants that indicate a customer’s ancestry.

The amount of the purchase was not reported and is 23andMe’s first acquisition, according to the San Francisco Business Times.

Deep Dive

Biotechnology and health

Google helped make an exquisitely detailed map of a tiny piece of the human brain

A small brain sample was sliced into 5,000 pieces, and machine learning helped stitch it back together.

The effort to make a breakthrough cancer therapy cheaper

CAR-T cells could revolutionize the treatment of a wide variety of diseases, if only we can make them cheaper.

Beyond Neuralink: Meet the other companies developing brain-computer interfaces

Companies like Synchron, Paradromics, and Precision Neuroscience are also racing to develop brain implants

Cancer vaccines are having a renaissance

After years of lackluster results, cancer vaccines seem poised for success. Finally.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.